Australia to Stop Reporting Cases of Myocarditis After Covid Vaccinations

Australia’s therapeutic goods administration (TGA) has announced that reports on myocarditis and pericarditis cases following mRNA-based COVID-19 vaccines by Pfizer and Moderna are not necessary anymore and will no longer be provided.

However, the TGA will “continue to monitor and review these adverse effects and will communicate any updated safety advice if needed,” they said in a statement.

According to the Food and Drug Administration, myocarditis (inflammation of the heart) and pericarditis (inflammation of the membrane surrounding the heart) are both regarded as side effects of mRNA vaccines produced by Pfizer and Moderna.

following more than 1,200 incidents of heart inflammation were recorded in persons following vaccination, the independent committee of vaccine experts at the Centers for Disease Control and Prevention also discovered a connection between heart inflammation and the mRNA vaccines.

According to data from the administration’s Database of Adverse Event Notifications (DAEN) as of July 17, there have been 3,823 incidents of pericarditis in Australia as a result of a COVID-19 vaccine, with six of those cases ending in death.

There have been 1,330 cases of myocarditis to date, with 17 resulting in death.

Cardiac Deaths On the Rise in Australia

The decision to stop reporting the deaths was made when the Australian Bureau of Statistics (ABS) found that in March 2023, the number of deaths resulting from cardiac disorders that were unrelated to ischemic heart disease was 19.8% higher than the baseline average.

They were nevertheless 0.8% lower than in March 2022.

In addition, there were 1.9 percent more cardiac fatalities overall from January to March 2023 than during the same time in 2022 and 17.5 percent more than the baseline norm.

In March 2023, the age-standardized death rate for those who died from other cardiac disorders was 2.1 per 100,000. The baseline average rate was 2.0, while the rate in March 2022 was 2.2, according to the ABS.

Myocarditis and mRNA Vaccines

European nations closely scrutinized the Spikevax (Moderna) after studies revealed an elevated incidence of myocarditis or pericarditis following a second dosage of the mRNA vaccines in male adolescents and young adults.

Soon after, the use of Moderna’s shots by children was prohibited in Sweden and other Nordic nations like Denmark, Norway, Finland, and Iceland.

The public health department of Canada has expressed concerns that cases appear to affect these groups the most frequently:

• adolescent and young adults
• males
• following a second dose
• typically occurring within seven days after vaccination.

Moderna is still permitted in Australia for those six years of age and older, despite data and replies from other countries, according to the TGA, which claims that the protective advantages outweigh any potential hazards.

According to the most recent data from the Australian Health Department,

“The advantages of receiving the Moderna vaccine much outweigh the danger of adverse reactions. Moderna is beneficial in preventing and defending against significant sickness from COVID-19 in adults 12 years of age and older, according to very large clinical trials.

Adults who received two doses of Moderna had a about 94% lower risk of contracting COVID-19 than those who did not receive the vaccination.

The vaccine was also successful in those over 65 and in teenagers between the ages of 12 and 17.

More than five million doses of Moderna have been given in Australia up till July 9, 2023.

The DAEN website reports that 7,452 of the 7,834 adverse responses to Moderna’s various vaccinations in Australia were directly related to the vaccine. Furthermore, 38 people have passed away as a result of bad reactions to Moderna Spikevax immunizations.

Moderna has been contacted by The Epoch Times for comment on the matter.

Since 2020, there have been 138,912 adverse reactions to all COVID-19 vaccines reported in Australia; of those, 135,323 were completely attributable to the vaccines, and there have been 995 documented fatalities.

A new recommendation on vaccinations has been made by the Australian Technical Advisory Group on Immunization (ATAGI), which advises the government on immunizations. Healthy Australians between the ages of 18 and 64 are now instructed they can decide whether or not to have a COVID-19 booster vaccine if they have already had an initial dose.

It is advised that Australians aged 5–17 who have complex medical disorders, as well as those aged 18–64 who have medical comorbidities that enhance their risk of severe COVID–19 or disability with large or complex health demands, receive a booster dosage.

The ATAGI does not advise giving a booster dose to any healthy youngster between the ages of 5 and 17, nevertheless.

SOURCES: ABS, CANADIAN GOVERNMENT, DAEN, AUSTRALIAN HEALTH DEPT, AUSTRALIAN GOVERNMENT